IEIS Secretary General Turgut Tokgoz On The Future Of Turkish Pharma: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
In the midst of negotiations over the government’s next pharmaceutical budget, the leader of the Pharmaceutical Manufacturers Association of Turkey sits down to talk about price cuts, GMP requirements and the future of the Turkish pharma industry.
You may also be interested in...
AiFD Vice Chairman Engin Guner On Price Cuts In Turkey And Mounting Pressure On Industry: An Interview With PharmAsia News (Part 1 of 2)
A former law maker and leader of the Turkish parliamentary delegation to the Council of Europe, Engin Guner knows about how policy works. The vice chairman of the Association of Research-Based Pharmaceutical Companies (AiFD), which represents Big Pharma in Turkey, emphasizes that government price cuts and related policy challenges, combined with currency depreciation, are taking a heavy toll on the industry.
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.